Shanrong Biotechnology Corp (SRBT) 收益

Shanrong Biotechnology Corp. operates as a shell company. The company is headquartered in Exton, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2008-12-01. The firm owns and operates three patents: Long-lasting preparation of long-term stable intravenous melatonin injectable addressing sepsis, bacterial pathologies, and other inflammatory pathology; new melatonin formulations for the treatment of chemotherapy-resistant tumors addressing cancer (head and neck, prostate, breast, ovarian, melanoma), and injectable melatonin composition for the treatment of viral diseases addressing coronavirus disease of 2019 (COVID-19) and other viral diseases.